EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

Julia L Glade Bender iD, Kerice Pinkney, Paul M Williams, Sinchita Roy-Chowdhuri iD, David R Patton, Brent D Coffey, Joel M Reid iD, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Nilsa C Ramirez und 9 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae096 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Oncologist, 2024. Verfasst von Julia L Glade Bender und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Hauptthemen laut MEDLINE: DNA Repair, Neoplasms, Phthalazines, Piperazines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial enrolled children aged 1-21 years with treatment-refractory solid tumors and predefined actionable genetic alterations. Patients with tumors harboring alterations in DNA damage repair (DDR) genes were assigned to receive olaparib.

Methods

Tumor and blood samples were submitted for centralized molecular testing. Tumor and germline sequencing were conducted in parallel. Olaparib was given twice daily for 28-day cycles starting at a dose 30% lower than the adult recommended phase 2 dose (RP2D). The primary endpoint was the objective response.

Results

Eighteen patients matched (1.5% of those screened) based on the presence of a deleterious gene alteration in BRCA1/2, RAD51C/D, or ATM detected by tumor sequencing without germline subtraction or analysis of loss of heterozygosity (LOH). Eleven (61%) harbored a germline mutation, with only one exhibiting LOH. Six patients enrolled and received the olaparib starting dose of 135 mg/m2/dose. Two participants were fully evaluable; 4 were inevaluable because <85% of the prescribed dose was administered during cycle 1. There were no dose-limiting toxicities or responses. Minimal hematologic toxicity was observed.

Conclusion

Most DDR gene alterations detected in Pediatric MATCH were germline, monoallelic, and unlikely to confer homologous recombination deficiency predicting sensitivity to olaparib monotherapy. The study closed due to poor accrual. ClinicalTrials.gov Identifier NCT03233204. IRB approved: initial July 24, 2017.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA RepairNeoplasmsPhthalazinesPiperazinesAdolescentAdultChildChild, PreschoolFemaleHumansInfantMaleYoung AdultAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinBRCA2 ProteinDNA DamageDNA-Binding ProteinsGerm-Line MutationPoly(ADP-ribose) Polymerase Inhibitors

Stichwörter der Autor:innen

DNA damage repairPARP inhibitionolaparibpediatric MATCH

Substanzen

Ataxia Telangiectasia Mutated ProteinsATM protein, humanBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanDNA-Binding ProteinsolaparibPhthalazinesPiperazines

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Department of Hematology-Oncology, Memorial Regional Hospital/Joe Dimaggio Children's Hospital, Hollywood, FL, United States.
  • Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
  • Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.

ORCID-Profile: Julia L Glade Bender, Sinchita Roy-Chowdhuri, Joel M Reid, Douglas S Hawkins, Margaret M Mooney

Förderung

  • NCI NIH HHS

Zitieren

APA

Glade Bender, J. L., Pinkney, K., Williams, P. M., Roy-Chowdhuri, S., Patton, D. R., Coffey, B. D., Reid, J. M., Piao, J., Saguilig, L., Alonzo, T. A., Berg, S. L., Ramirez, N. C., Fox, E., Weigel, B. J., Hawkins, D. S., Mooney, M. M., Takebe, N., Tricoli, J. V., Janeway, K. A., …, & Parsons, D. W. (2024). Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. The Oncologist. https://doi.org/10.1093/oncolo/oyae096

Vancouver

Glade Bender JL, Pinkney K, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, et al. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. The Oncologist. 2024. doi:10.1093/oncolo/oyae096

BibTeX
@article{GladeBender2024,
  author = {Glade Bender, Julia L and Pinkney, Kerice and Williams, Paul M and Roy-Chowdhuri, Sinchita and Patton, David R and Coffey, Brent D and Reid, Joel M and Piao, Jin and Saguilig, Lauren and Alonzo, Todd A and Berg, Stacey L and Ramirez, Nilsa C and Fox, Elizabeth and Weigel, Brenda J and Hawkins, Douglas S and Mooney, Margaret M and Takebe, Naoko and Tricoli, James V and Janeway, Katherine A and Seibel, Nita L and Parsons, Donald W},
  title = {Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae096}
}
Kostenlos starten →